The prognosis for patients with systemic lupus erythematosus (SLE) has improved
significantly, with 20-year survival now approximately 80% owing partly to effective …

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by
periods of flares and remission, resulting in organ damage over time caused by persistent …

Systemic lupus erythematosus (SLE) is characterized by uncontrolled secretion of
autoantibodies by plasma cells. Although the functional importance of plasma cells and …

OBJECTIVE: To review and summarize published information on the effectiveness and
safety of rituximab (RTX) in adult patients with refractory neuropsychiatric systemic lupus …

Although corticosteroids and immunosuppressants are widely used for the treatments of
systemic lupus erythematosus (SLE), safer and more effective therapies are prerequisite. We …

During the past 10 yrs, over 700 patients suffering from severe autoimmune disease (AD)
have received an autologous haematopoietic stem cell transplant as treatment of their …

B cell-depletion therapy, particularly using anti-CD20 treatment, has provided proof of
concept that targeting B cells and the humoral response may result in clinical improvements …

OBJECTIVE: To describe the safety and efficacy of rituximab in the treatment of childhood-
onset systemic lupus erythematosus (SLE). STUDY DESIGN: We conducted a French …

Systemic lupus erythematosus is an autoimmune multi-system disease of uncertain
aetiology with highly variable clinical manifestations. Women of child-bearing age are most …

Objectives To investigate key factors that may contribute to the variability of rituximab-
mediated peripheral and renal B cell depletion (BCD) in SLE. Methods We analysed:(i) …